Evonik forms lysine JV in Russia

The facility is expected to open in 2014 in Volgodonsk at a cost of about $200 million.

 

Evonik, based in Essen, Germany, is a minority partner in the joint venture, although the company says it has an option to increase its share "significantly."

 

The project has the backing of the governor of the Rostov region where the plant will be built, Evonik says.

 

Evonik and RusBiotech say they are also in talks with the state-owned Russian Corporation of Nanotechnologies about its possible acquisition of a stake in the joint venture.

 

Rusnano is increasing its ties with Western firms, having recently invested in a joint venture with US-based Cleveland BioLabs and with the U.K.’s Pro Bono Bio.

 

The lysine venture is the latest of several moves made by Evonik recently to increase its presence in the amino acid market. Notably, the firm is doubling lysine capacity at its plant in Blair, Nebraska, and has announced plans to build a new DL-methionine plant in Singapore at a cost of $500 million.

 

The planned Russian facility will be based on about 300,000 metric tons per year of wheat grown in the Rostov region.